rizatriptan has been researched along with Bilateral Headache in 13 studies
rizatriptan: structure given in first source; RN given refers to benzoate
| Excerpt | Relevance | Reference |
|---|---|---|
| " Identical randomized double-blind studies were conducted comparing the efficacy of rizatriptan 10 mg or placebo administered within 1 h of headache onset, while pain was mild." | 5.12 | Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies. ( Cady, R; Hustad, C; Martin, V; Mauskop, A; Ramsey, K; Rodgers, A; Skobieranda, F, 2007) |
| "To evaluate the pharmacokinetic profile and tolerability of single doses of rizatriptan oral disintegrating tablets (ODTs) in pediatric migraineurs." | 2.77 | Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study. ( Fraser, IP; Han, L; Han, TH; Hreniuk, D; Li, CC; Linder, S; Stoch, SA; Wagner, JA; Winner, P, 2012) |
| "Rizatriptan is an effective treatment for MRM." | 2.73 | A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine. ( Bigal, M; Ho, TW; Rapoport, A; Sheftell, F; Tepper, D; Tepper, S, 2008) |
| " For preventive migraine treatment, the Childhood and Adolescent Migraine Prevention trial demonstrated that approximately 60% of children and adolescents with migraine will improve with a three-pronged treatment approach that includes: (1) lifestyle management counseling (on sleep, exercise, hydration, caffeine, and avoidance of meal skipping); (2) optimally dosed acute therapy, specifically nonsteroidal anti-inflammatory drugs and triptans; and (3) a preventive treatment that has some evidence for efficacy." | 2.58 | Pediatric and Adolescent Headache. ( Gelfand, AA, 2018) |
| "Photophobia was demonstrated using a modified elevated plus maze in which the safe closed arms were brightly illuminated; mutant mice avoided the light despite showing no differences in the standard (anxiety) version of the test." | 1.39 | Behavioral evidence for photophobia and stress-related ipsilateral head pain in transgenic Cacna1a mutant mice. ( Atlin, C; Baran, I; Chanda, ML; Ferrari, MD; Guindi, D; Hathaway, G; Israelian, N; Levenstadt, J; Low, D; Macrae, L; Mariette Lenselink, A; Mogil, JS; O'Shea, L; Silver, A; Spijker, S; Tuttle, AH; van den Maagdenberg, AM; Zendegui, E, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chanchlani, R | 1 |
| Agrawal, A | 1 |
| Janjua, D | 1 |
| Hafsa, SN | 1 |
| Gelfand, AA | 1 |
| Chanda, ML | 1 |
| Tuttle, AH | 1 |
| Baran, I | 1 |
| Atlin, C | 1 |
| Guindi, D | 1 |
| Hathaway, G | 1 |
| Israelian, N | 1 |
| Levenstadt, J | 1 |
| Low, D | 1 |
| Macrae, L | 1 |
| O'Shea, L | 1 |
| Silver, A | 1 |
| Zendegui, E | 1 |
| Mariette Lenselink, A | 1 |
| Spijker, S | 1 |
| Ferrari, MD | 1 |
| van den Maagdenberg, AM | 1 |
| Mogil, JS | 1 |
| Bigal, M | 1 |
| Sheftell, F | 1 |
| Tepper, S | 1 |
| Tepper, D | 1 |
| Ho, TW | 1 |
| Rapoport, A | 1 |
| Satow, T | 1 |
| Saiki, M | 1 |
| Kishi, Y | 1 |
| Fukuda, M | 1 |
| Nakaoku, T | 1 |
| Nakatani, K | 1 |
| Fraser, IP | 1 |
| Han, L | 1 |
| Han, TH | 1 |
| Li, CC | 1 |
| Hreniuk, D | 1 |
| Stoch, SA | 1 |
| Wagner, JA | 1 |
| Linder, S | 1 |
| Winner, P | 1 |
| Silberstein, SD | 1 |
| Diener, HC | 2 |
| McCarroll, KA | 1 |
| Lines, CR | 1 |
| Cady, R | 1 |
| Martin, V | 1 |
| Mauskop, A | 1 |
| Rodgers, A | 1 |
| Hustad, C | 1 |
| Ramsey, K | 1 |
| Skobieranda, F | 1 |
| Tfelt-Hansen, P | 1 |
| Rapoport, AM | 1 |
| Tepper, SJ | 1 |
| Katsarava, Z | 1 |
| Fritsche, G | 1 |
| Muessig, M | 1 |
| Limmroth, V | 1 |
| van der Post, J | 1 |
| Schram, MT | 1 |
| Schoemaker, RC | 1 |
| Pieters, MS | 1 |
| Fuseau, E | 1 |
| Pereira, A | 1 |
| Baggen, S | 1 |
| Cohen, AF | 1 |
| van Gerven, JM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Single-Dose Pharmacokinetics of MK0462 in Subjects With Migraines Aged 6 to 17 Years[NCT00604812] | Phase 1 | 31 participants (Actual) | Interventional | 2007-12-17 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00095004] | Phase 3 | 167 participants (Actual) | Interventional | 2004-10-21 | Completed | ||
| A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild[NCT00092963] | Phase 3 | 529 participants (Actual) | Interventional | 2004-08-17 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Preliminary pharmacokinetics data; Apparent half-life (t½) (NCT00604812)
Timeframe: 24 Hours
| Intervention | Hours (Mean) |
|---|---|
| Panel A Rizatriptan | 1.3 |
| Panel B Rizatriptan | 1.6 |
| Panel C Rizatriptan | 1.6 |
Preliminary pharmacokinetics data; Maximum concentration (Cmax); i.e, highest concentration of drug achieved (NCT00604812)
Timeframe: 24 Hours
| Intervention | ng/mL (Mean) |
|---|---|
| Panel A Rizatriptan | 24.6 |
| Panel B Rizatriptan | 25.0 |
| Panel C Rizatriptan | 18.4 |
Preliminary pharmacokinetics data; Time to maximum concentration (Tmax); i.e., amount of time required to reach maximum concentration (NCT00604812)
Timeframe: 24 Hours
| Intervention | Hours (Median) |
|---|---|
| Panel A Rizatriptan | 1.0 |
| Panel B Rizatriptan | 1.5 |
| Panel C Rizatriptan | 1.3 |
Preliminary pharmacokinetics data; Area Under the Curve (AUC(0-∞)); i.e., area under the concentration-time plot (NCT00604812)
Timeframe: 24 Hours
| Intervention | ng hr/mL (Mean) |
|---|---|
| Panel A Rizatriptan | 59.4 |
| Panel B Rizatriptan | 84.0 |
| Panel C Rizatriptan | 67.93 |
All adverse experiences spontaneously reported by subject and/or observed by investigator and repeated clinical evaluation of physical examinations, vital signs, 12-lead ECG (electrocardiogram) and laboratory safety tests (hematology/blood chemistry/urinalysis) (NCT00604812)
Timeframe: 24 Hours
| Intervention | Participants (Number) | ||
|---|---|---|---|
| Serious Adverse Events | Non-Serious Adverse Events | No Adverse Events Reported | |
| Placebo | 0 | 3 | 4 |
| Rizatriptan 10 mg | 0 | 7 | 7 |
| Rizatriptan 5 mg | 0 | 3 | 7 |
3 reviews available for rizatriptan and Bilateral Headache
| Article | Year |
|---|---|
The Efficacy of Different Triptans for the Treatment of Acute Headache in Pediatric Migraine: A Systematic Review.
Topics: Adolescent; Child; Headache; Humans; Migraine Disorders; Naproxen; Sumatriptan; Tryptamines | 2023 |
Pediatric and Adolescent Headache.
Topics: Adolescent; Child; Disease Management; Headache; Humans; Pediatrics; Serotonin Receptor Agonists; Tr | 2018 |
Triptans are all different.
Topics: Carbazoles; Headache; Humans; Indoles; Oxazolidinones; Pyrrolidines; Serotonin Receptor Agonists; Su | 2001 |
5 trials available for rizatriptan and Bilateral Headache
| Article | Year |
|---|---|
A randomized double-blind study comparing rizatriptan, dexamethasone, and the combination of both in the acute treatment of menstrually related migraine.
Topics: Cross-Over Studies; Dexamethasone; Drug Therapy, Combination; Female; Headache; Humans; Menstruation | 2008 |
Pharmacokinetics and tolerability of rizatriptan in pediatric migraineurs in a randomized study.
Topics: Adolescent; Child; Double-Blind Method; Female; Headache; Humans; Male; Migraine Disorders; Triazole | 2012 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Symptoms of cutaneous sensitivity pre-treatment and post-treatment: results from the rizatriptan TAME studies.
Topics: Adult; Comorbidity; Double-Blind Method; Female; Headache; Humans; Hyperalgesia; Male; Migraine Diso | 2007 |
Clinical features of withdrawal headache following overuse of triptans and other headache drugs.
Topics: Adult; Analgesics; Drug Therapy, Combination; Ergotamine; Female; Headache; Humans; Indoles; Male; M | 2001 |
CNS effects of sumatriptan and rizatriptan in healthy female volunteers.
Topics: Adult; Affect; Brain; Cognition; Cross-Over Studies; Dizziness; Double-Blind Method; Electroencephal | 2002 |
5 other studies available for rizatriptan and Bilateral Headache
| Article | Year |
|---|---|
Behavioral evidence for photophobia and stress-related ipsilateral head pain in transgenic Cacna1a mutant mice.
Topics: Analgesics; Animals; Calcium Channels, L-Type; Calcium Channels, N-Type; Disease Models, Animal; Dos | 2013 |
Rizatriptan is effective for headache in a patient with meningeal carcinomatosis.
Topics: Brain Neoplasms; Female; Headache; Humans; Meningeal Carcinomatosis; Middle Aged; Serotonin Receptor | 2011 |
[New onset headache. Which patients should be sent for CT imaging?].
Topics: Acute Disease; Brain Diseases; Diagnosis, Differential; Drug Administration Schedule; Headache; Huma | 2002 |
CNS effects of sumatriptan and rizatriptan.
Topics: Adult; Affect; Brain; Cognition; Cross-Over Studies; Dizziness; Double-Blind Method; Electroencephal | 2004 |
A comment on time-to-event analysis for headache relief.
Topics: Analgesics; Headache; Humans; Indoles; Oxazolidinones; Piperidines; Randomized Controlled Trials as | 2000 |